...
Time's of the essence. Let me get straight to it.

StockWireNews

Coverage Cont: Low Float (SILO) Could Become A Major Bounce Idea Near Term (Key Technicals Turn Oversold)

October 19th

Greetings Readers,

Time's of the essence. Let me get straight to it.

After Wednesday morning's alert went on a wild run of 31% intraday from its open to its high, it's time to get a specific Nasdaq profile back on radar.

Why? Because it may become a major bouncer come Thursday's opening bell.

Here's the concise version...

Silo Pharma, Inc. (SILO) needs complete attention near term based on key technical indicators heading into oversold territory.

On Wednesday, SILO was displaying several oversold technicals that could signal an upcoming reversal/bounce may be nearing.

They include the following:

  • 14-Day Raw Stochastic: 9.47%
  • 14-Day Williams %R: 90.53%
  • 9-Day Relative Strength Index (RSI): 31.67%
  • 14-Day Relative Strength Index: 35.74%

When these technicals move into the current levels they're at, they can appear oversold and undervalued.

The last time SILO dropped down to the mid $4.00 range back at the end of September, it went on a major $2.00 run in the blind of an eye back to $6.50.

Part of the reason this was able to happen is because of SILO's extremely tiny float that Yahoo Finance is reporting to be 1.82Mn.

When a float is that small, volatility can crop up at any moment's notice.

I'm not saying that SILO is going to surge multiple dollars this week, but the potential is there and the chart shows how high this profile was trading at in the recent term.

Now, pair all that knowledge with this solid press release from October: Silo Pharma extends research pact for Alzheimer’s and Stress Induced Anxiety Therapeutics

Could this news bring even more attention to SILO near term?

Take a second now and get SILO back on radar ahead of Thursday's opening bell.

-----

A recent Harvard study shared some pretty unsettling news.(1)

The medical cost of mental health conditions is estimated to rise to $6Tn by 2030.

And with the way the global news reads every day, mental health will definitely be something to watch closely in the years ahead.

One such market that has been growing significantly and gaining traction in the treatment of such issues and additional diseases is the psych-e-delics as treatment market.

Data Bridge Market Research analyses that the market is growing at such a rate that it could $8Bn by 2029.(2)

In other words, opportunities abound.

And one company I want to bring to your attention could be well-positioned to make a name for themselves in these growing markets.

Plus, with a tiny float, big October news, and a recent Nasdaq uplisting that could add tons of exposure to the company, there's only one profile to have at the top of your watch-list Thursday:

Silo Pharma, Inc. (SILO)

Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psych-e-delic research for people suffering from indications such as PTSD, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry.

And based on these potential catalysts, SILO needs to be put on breakout watch. Check them out:

No. 1 - Low Float Volatility Could Pop Up On Daily Basis

No. 2 - Initiation Of A Preclinical Tox. Study Signals Company's SP-26 Formulation Moving In Right Direction

No. 3 - SILO Pursues Regulatory Pathway For Key Topical Formulation

No. 4 - Huge Nasdaq Uplisting News Could Add Tons Of Exposure

No. 5 - Company's Patent Portfolio Continues To Grow...

But more on those in a second...

The Silo Difference

The company is committed to developing innovative solutions to address a variety of underserved conditions including Alzheimer’s; Parkinson’s; Multiple Sclerosis (MS); Rheumatoid Arthritis (RA); and Stress-Induced Psychiatric Disorders.

While partnering with some of the leading Academic Institutions, Silo has licensed therapeutics that will allow the company to pursue the more streamlined 505(b)(2) route for trials.

Silo anticipates this strategy will lower cost and allow for a faster approval process to help patients with few if any proven addressable therapeutics.

Pipeline - Showing Promise In A Range Of Illnesses And Diseases

image

SPC-14 - Targeting Alzheimer’s

Regulatory Pathway & Results

  • 505(b)(2) Pathway
  • Preclinical testing and proof-of-concept being lead by inventor Dr. Christine Denny of Columbia University
  • SPC-14 has shown reduced hyponeophagia in animal studies
  • SPC-14 may reduce behavioral despair
  • Silo has licensed technology with Columbia and has recently entered into a scientific research agreement with Dr. Denny’s lab

Market Opportunity - Alzheimer’s Disease

  • 6.5 million Americans suffer from Alzheimer’s and related diseases
  • ~1 in 9 Americans 65+ have Alzheimer’s
  • U.S. market for relevant drugs expected to reach $5Bn by 2027

-----

SPC-15 - Targeted prophylactic treatment—Stress-induced affective disorders

Applications

  • Sponsored Research Agreement with Columbia University Prevention of stress-induced affective disorders
  • Increasing stress resilience in military, first responders, and other populations at high risk of PTSD
  • Predicting the level of severity or progression such disorders
  • Molecular targets for use in drug discovery of innovative treatments

Market Opportunity

  • 26% of Americans 18+ suffer from anxiety, PTSD and other disorders
  • This number has escalated post-CV-19
  • U.S. market for relevant drugs expected to reach $13Bn by 2027

-----

SP-26 - Time-Released Psi-lo-cybin, Keta-mine

Applications

  • Deliver Keta-mine or Psi-lo-cybin in a time-released manner
  • Will time-release diminish the hallucinogenic effects of these psych-e-delics
  • Pre clinical study underway shows Z-pod can hold and distribute Keta-mine
  • Efficacy study in animals underway

-----

SPU-16 - CNS Homing Peptide

Regulatory Pathway & Results 505(b)(2) Pathway

  • May be used as a delivery tool to target current therapies to detect inflammation in the spinal cord
  • May be used for diagnosing and monitoring MS
  • Decreases toxicity of existing therapeutics
  • Animal study results show much improved delivery of therapeutics and decreased toxicity.

Market Opportunity

  • There are approximately 400,000 Americans and 2.5 million people worldwide with MS
  • The most widespread disabling neurological condition of young adults
  • Global market for MS drugs expected to reach $25.3Bn by 2027

-----

SPU-21 - Arthritogenic Joint Homing Peptides Utilizing Psi-lo-cybin

Applications

  • Identify markers of arthritic inflammation in joints
  • Isolate phage clones that preferentially target inflamed joints of arthritic Lewis rats
  • Peptide significantly inhibited arthritic progression in this animal model
  • Further studies are underway at UMB

Market Opportunity

  • 1.3Mn U.S. adults suffer from RA
  • The most common autoimmune disease in U.S.
  • U.S. market for RA drugs expected to reach $63Bn by 2027

Grab more key company details/sources here.

-----

Right now, SILO has several potential catalysts that could provide it with a breakout spark. Here's what to know:

No. 1 SILO Potential Catalyst - Low Float Volatility Could Pop Up On Daily Basis

According to the Yahoo Finance website, SILO has a low float.

The website reports this profile to have approximately 1.82Mn shares in its float.

Why is that important? It's important on one crucial level. Volatility.

Could more 2022 positive company news help provide a near term spark?

-----

No. 2 SILO Potential Catalyst - Initiation Of A Preclinical Tox. Study Signals Company's SP-26 Formulation Moving In Right Direction

Silo Pharma Initiates Toxicity Study of its Proprietary Keta-mine Formulation for Treatment of Fibromyalgia

Studies of SP-26, the company’s proprietary, time-released keta--mine show positive results in reducing neuropathic nerve pain

ENGLEWOOD CLIFFS, NJ, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has initiated a preclinical toxicity study of its novel time-released, dosage controlled formulation of keta-mine, designated as SP-26, for the treatment of fibromyalgia.

Eric Weisblum, CEO of Silo Pharma, commented, “We are working closely with our joint venture partner Zylö Therapeutics in developing a topical sustained released keta-mine utilizing Z-pod™ technology. Preclinical studies have already shown that our joint developed delivery method and formulation can hold and distribute keta-mine in a time-released manner. SP-26 reported positive results in reducing neuropathic nerve pain. This safety evaluation study will uncover maximum tolerated dosing data that will inform our future trials.

...

Read the full article here.

-----

No. 3 SILO Potential Catalyst - SILO Pursues Regulatory Pathway For Key Topical Formulation

Silo Pharma Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released Keta-mine Technology

Company intends to pursue 505(b)(2) regulatory pathway for novel topical formulation of keta-mine

ENGLEWOOD CLIFFS, NJ, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psych-e-delic research, today announced that it is working with Premier Consulting as its regulatory partner to assist with the preparation of a pre-Investigational New Drug (IND) package and meeting request with the United States Food and Drug Administration (FDA) for a novel topical formulation of keta-mine, designated as SPC-26, for the treatment of fibromyalgia.

Premier Consulting will assist the Company with the development of its nonclinical, clinical, clinical pharmacology, and biopharmaceutics strategy and program to be proposed to the FDA. The submission of a pre-IND meeting request for collaborative discussions with the FDA will be made in anticipation of the filing a clinical IND package.

We are confident that our highly constructive pre-clinical work on SP-26 will offer strong support for our pre-IND package as we seek to advance our time-released keta-mine delivery system into the clinic,” said CEO Eric Weisblum. “We intend to pursue the 505(b)(2) regulatory pathway and have engaged Premier Consulting as a true strategic partner to pave the way for productive discussions and alignment with the FDA.

...

Read the full article here.

-----

No. 4 SILO Potential Catalyst - Huge Nasdaq Uplisting News Could Add Tons Of Exposure

Silo Pharma Announces Uplisting to Nasdaq Capital Market and Pricing of $5Mn Public Offering of Common St-ock

Silo Pharma common stock to begin trading on Nasdaq Tuesday, September 27, 2022, under the symbol “SILO”

ENGLEWOOD CLIFFS, NJ , Sept. 27, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (formerly OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psych-e-delic research, today announced pricing of an underwritten public offering of 1Mn shares of its common st-ock at a price to the public of $5.00 per share.

The gross proceeds to Silo Pharma from this offering are expected to be $5Mn, before deducting the underwriting discount and other estimated offering expenses payable by Silo Pharma. Silo Pharma intends to use the net proceeds from the offering for product development, marketing, and working capital and general corporate purposes. A portion of the proceeds may also be used for acquisitions of complementary businesses, technologies, or other assets.

As a result of the offering, the Company’s common stock will become listed on the Nasdaq Capital Market and will trade under the ticker symbol “SILO” beginning September 27, 2022. The offering is expected to close on or about September 29, 2022, subject to customary closing conditions. In addition, the Company has granted a 45-day option to the underwriter to purchase up to an additional 150,000 shares of common st-ock at the public offering price, less the underwriting discount, to cover over-allotments, if any.

...

Read the full article here.

-----

No. 5 SILO Potential Catalyst - Company's Patent Portfolio Continues To Grow...

Silo Pharma Expands License Agreement and Patent Portfolio

Silo Enters into Commercial Evaluation License Agreement for Next Generation Liposomes

Therapeutics Would Target Multiple Diseases Including Autoimmune Disorders

ENGLEWOOD CLIFFS, N.J., June 23, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of traditional and psych-e-delics as a therapeutic, today announced that it has expanded its Commercial Evaluation License Agreement (CELA) with the University of Maryland Baltimore (UMB) for its next generation Liposomal Peptide targeting autoimmune diseases.

Eric Weisblum, CEO of Silo Pharma commented, “We are delighted to expand our partnership with UMB. Pre-clinical testing of these peptides has shown positive results in animal studies. The three-phage peptides we identified specifically target inflamed vascular endothelium of arthritic joints in an adjuvant-induced arthritis rat model. To test the therapeutic effect of the peptides, arthritic Lewis rats (n=4/group) were injected intravenously with one of the peptides or PBS either at the onset or just following the onset of arthritis. The rats were monitored regularly for disease severity and were assigned an 'arthritic score.' The results show treatment of arthritic Lewis rats with two of the three phage-encoded peptides (NQR and RGD) suppresses adjuvant arthritis, with RGD producing the most robust effect. Therefore, phage peptides ADK homes to the synovial vasculature of the inflamed joint, while phage peptides NQR and RGD both home to this area of the inflamed joint and have a therapeutic effect in a rat model of arthritis. The global market for auto-immune disease therapeutics is projected to be over $150Bn by 2025. We believe the issued patent portfolio that comes with these assets allows Silo to further advance its value to in-vest-ors and future partners.

Read the full article here.

-----

SILO Recap - Key Potential Breakout Catalysts To Know Now

No. 1 - Low Float Volatility Could Pop Up On Daily Basis

No. 2 - Initiation Of A Preclinical Tox. Study Signals Company's SP-26 Formulation Moving In Right Direction

No. 3 - SILO Pursues Regulatory Pathway For Key Topical Formulation

No. 4 - Huge Nasdaq Uplisting News Could Add Tons Of Exposure

No. 5 - Company's Patent Portfolio Continues To Grow...

-----

Coverage is officially initiated on SILO. When time permits, do this:

image

Get SILO on your radar now.

Sincerely,

Kai Parker

StockWireNews


Source 1
Source 2


(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)

StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company. Disclosure: I am not a lice.nsed finan.cial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. StockWireNews full disclosure is to be read and fully understood before using StockWireNews website, or joining StockWireNews' email or text list. By viewing StockWireNews website and/or reading StockWireNews email or text newsletter you are agreeing to StockWireNews full disclosure which can be read at www.stockwirenews.net/disclosure An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns and operates fierceinvestor . com (“FI”), and owns and operates stockstreetwire . com ("SSW"). From time to time, StockWireNews, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Ownership of "FI" and "SSW" has now moved to a single individual. Pursuant to an agreement between SWN Media LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 10/12/22 and ending on 10/13/22 to publicly disseminate information about (SILO) via Website, Email and SMS. SWN Media LLC was paid twenty-five thousand USD via bank wire transfer. We own zero shares of (SILO). We have not been compensated for today's update on profile (SILO). We own zero shares of (SILO). A member of SWN Media LLC is also a member of TD Media LLC. Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 10/20/2022 and ending on 10/20/2022 to publicly disseminate information about (SILO:US) via digital communications. We have been paid an additional seventeen thousand five hundred dollars USD via bank wire transfer. To date we have been paid eighty thousand dollars USD via bank wire transfer to disseminate information about (SILO:US) via digital communications. We own zero shares of (SILO:US). lifewatermedia.com/silo-disclaimer-24/